About Careers MedBlog Contact us
Medindia LOGIN REGISTER
Advertisement

New Biomarker Found to Improve Leukemia Treatment

by Madhumathi Palaniappan on January 12, 2017 at 11:19 AM
Font : A-A+

New Biomarker Found to Improve Leukemia Treatment

Novel biomarker helps to detect patients who respond for leukemia treatment when compared to non-responders with high accuracy, finds a research team from Goethe-University Frankfurt.

The research team provides new hope for patients who cannot be effectively treated for leukemia.

Advertisement


Acute myeloid leukemia (AML) is a cancer that leads to abnormal proliferation of white blood cells.

The anti-cancer drug cytarabine provides the basis of chemotherapies directed against AML. Cytarabine needs to be activated in cancer cells by the addition of phosphate groups to exert its anti-cancer effects. Prof Jindrich Cinatl (Institut für Medizinische Virologie, Goethe-Universität, Acting Director: Prof Volkhard Kempf) investigated with his research group (funded by the Frankfurter Stiftung für krebskranke Kinder) cytarabine-resistant AML cells from the Resistant Cancer Cell Line (RCCL) collection that he runs together with Prof Martin Michaelis (University of Kent, Canterbury, UK).
Advertisement

Prof Cinatl discovered that the toxicity of cytarabine against AML cells correlates with the expression of the cellular enzyme SAMHD1, which enables to predict the sensitivity of AML cells to cytarabine.

Following this initial finding, a consortium led by Prof Cinatl together with Prof Oliver Keppler (who moved from the Institut für Medizinische Virologie, Goethe-Universität to Ludwig-Maximilians-Universität, München during the project) showed that SAMHD1 removes the phosphate residues from the active form of cytarabine and thereby reverses it into its inactive state.

In a cooperation with clinicians (led by Prof Hubert Serve, Medizinische Klinik II, Goethe-Universität) it was shown that SAMHD1 levels determined in leukaemia cells also enabled the prediction of the response of AML patients to cytarabine-based chemotherapies with high accuracy. This introduces SAMHD1 as clinical biomarker that can guide cytarabine-based chemotherapies only to such patients that are very likely to respond and spares patients who are unlikely to respond from toxic side effects.

In addition, the Frankfurt-led team showed that inhibition of SAMHD1 effectively sensitises cytarabine-resistant AML cells to cytarabine-based chemotherapies, opening future prospects for the treatment of patients for whom currently no effective therapy exists.



Source: Eurekalert
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
What's New on Medindia
Macronutrients Calculator for Weight Loss
Quiz on Kidney
World Disability Day 2022 - The Role of Innovative Transformation
View all
Recommended Reading
News Archive
Date
Category
Advertisement
News Category

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Leukemia Chronic Myeloid Leukemia Acute Myeloid Leukemia Acute Lymphoblastic Leukemia Multiple Myeloma Bone Marrow Transplantation Hairy Cell Leukemia 

Most Popular on Medindia

Post-Nasal Drip Loram (2 mg) (Lorazepam) Vent Forte (Theophylline) Color Blindness Calculator Selfie Addiction Calculator Indian Medical Journals Find a Hospital Blood Donation - Recipients Hearing Loss Calculator Drug Interaction Checker
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close
×

New Biomarker Found to Improve Leukemia Treatment Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests